Paul Edick

Biography

Mr. Paul Edick became a Director for Sucampo in July 2016. He currently serves as Founding Partner at 3G Advisors, a consultancy to the pharmaceutical, healthcare and healthcare investor communities. From 2010 to 2014, Mr. Edick was Chief Executive Officer and board member of Durata Therapeutis, a public biopharmaceutical company addressing the growing need for new antibiotics to treat infectious diseases. Prior to Durata, he was Chief Executive Officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus investment search vehicle, and prior to that he was Chief Executive Officer at MedPoint Healthcare, Inc. Mr. Edick has also held a number of senior positions at GD Searle & Company, and at Pharmacia Corporation following its acquisition of the company, culminating in his appointment as Pharmacia’s Group Vice President and President for Asia and Latin America. He is a member of the Board of Directors of PDL BioPharma, Inc., NewLink Genetics, Inc. and Neos Therapeutics, Inc. Mr. Edick is also Chairman of the Board of Iterum Therapeutics, a private company. Mr. Edick earned a bachelor’s degree in Psychology from Hamilton College in Clinton, NY.

Research Interest

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan, Switzerland and the U.K.